These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20180789)

  • 21. Dexlansoprazole MR: a review.
    Hershcovici T; Jha LK; Fass R
    Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study.
    Thomson AB; Cohen P; Ficheux H; Fiorentini P; Domagala F; Homerin M; Taccoen A
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1179-87. PubMed ID: 16611279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion.
    Metz DC; Devlin JW; Vakily M; Atkinson S; Lloyd E
    Pharmacotherapy; 2008 Mar; 28(3):301-7. PubMed ID: 18294109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.
    Kukulka M; Eisenberg C; Nudurupati S
    Clin Exp Gastroenterol; 2011; 4():213-20. PubMed ID: 22016582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):21-2. PubMed ID: 19305367
    [No Abstract]   [Full Text] [Related]  

  • 26. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
    Howden CW
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR; Marzella N
    Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
    Croxtall JD; Scott LJ
    Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
    Heyman MB; Zhang W; Huang B; Chiu YL; Amer F; Winter HS
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):35-40. PubMed ID: 17204950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
    Grabowski B; Lee RD
    Clin Drug Investig; 2012 May; 32(5):319-32. PubMed ID: 22455762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.
    Kukulka M; Nudurupati S; Perez MC
    Therap Adv Gastroenterol; 2016 Nov; 9(6):759-769. PubMed ID: 27803731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
    Grady H; Murakawa Y; Mulford D; Kukulka M
    J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
    Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
    Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG; Gebbie J; Home PD
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
    Miner PB; Allgood LD; Grender JM
    Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.
    Pais SA; Nathwani RA; Dhar V; Nowain A; Laine L
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1607-13. PubMed ID: 16696810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
    Kukulka M; Nudurupati S; Perez MC
    Therap Adv Gastroenterol; 2016 Nov; 9(6):770-780. PubMed ID: 27803732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation.
    Röhss K; Wilder-Smith C; Bokelund-Singh S; Sagar M; Nagy P
    Dig Dis Sci; 2010 Dec; 55(12):3423-9. PubMed ID: 20238247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.